Rheumatoid Arthritis (RA) Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects
The objective of the study is to assess the single dose PK, safety, tolerability and immunogenicity of abatacept 125mg administered SC in Chinese healthy subjects.
n/a
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047341 -
A Study of Human Substance Balance and Biotransformation of [14C]SHR0302
|
Phase 1 | |
| Withdrawn |
NCT02786563 -
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
|
||
| Completed |
NCT03257852 -
A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate
|
Phase 2 | |
| Completed |
NCT03660059 -
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
|
Phase 3 | |
| Recruiting |
NCT03971253 -
Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
|
||
| Not yet recruiting |
NCT05486715 -
Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients
|
||
| Completed |
NCT03682705 -
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
|
Phase 2 | |
| Active, not recruiting |
NCT04574492 -
A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
|
||
| Completed |
NCT01871961 -
Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient
|
Phase 1 | |
| Completed |
NCT04497597 -
A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
|
||
| Terminated |
NCT02775656 -
UCB Cimzia Pregnancy Follow-up Study
|
||
| Completed |
NCT01173120 -
Methotrexate - Inadequate Response Device Sub-Study
|
Phase 3 | |
| Completed |
NCT03223012 -
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
|
||
| Completed |
NCT03086343 -
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
|
Phase 3 | |
| Terminated |
NCT01569152 -
Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)
|
Phase 2 | |
| Completed |
NCT02105129 -
A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
|
Phase 1 | |
| Completed |
NCT01618968 -
Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
|
Phase 2 | |
| Completed |
NCT01618955 -
Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device
|
Phase 2 | |
| Completed |
NCT01577563 -
Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).
|
N/A | |
| Completed |
NCT03339089 -
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
|